TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mammographic breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HBA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin sensitivity as Quantitative Insulin Sensitivity Check Index (QUIKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of errors during PVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Corticostriatal Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-treatment TSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease pain on injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural history of Amelogenesis Imperfecta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Acute Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Oxford Knee Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Seizure cessation within 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: AMH levels in dried bloodspot vs serum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: side effects and complications of urinary catheter usage
Endpoint domain: Adverse events/effects
Primary endpoint: Change in radiographic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in self-reported hip questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants With ACR Pedi 30 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Establish B Cell Aplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of pain, stiffness, clicking or locking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and efficacy assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: weight gain in g/kg/d
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability of intravenous voriconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Glogau Photodamage Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pleural effusions after coronary artery bypass graft surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absence of pneumothorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change From Baseline in 24-Hour Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change From Baseline in 24-Hour Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Percentage Change From Baseline in Glucose Area Under the Plasma Concentration Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percentage Change From Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in Heart Rate Measured by Electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of suspicious lesions identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Length of Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Change in Best-corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed to perform vesicourethral anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: postoperative dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: postoperative dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Daily minutes of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Daily step count
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time without nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Discontinued From Study Due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Changes in Physical Examination Findings
Endpoint domain: Adverse events/effects
Primary endpoint: Patients Needing Expedited Follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Costs Associated With Traditional Face to Face Consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Toxicity occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral and cellular immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes From Baseline in Fasting Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes From Baseline in 2 h Oral Glucose Tolerance Test (OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With at Least One Positive SARS-CoV-2 Antibody Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of etiologies of cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Feasibility of patient consent and randomization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of treatment switch
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Therapeutic Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first event
Endpoint domain: Mortality/survival
Primary endpoint: Impact of Events Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalized Anxiety Disorder 7 (GAD-7) Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire 9 (PHQ-9) Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact of Nausea and Vomiting on Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful infection of controlled P. vivax sporozoite human challenge
Endpoint domain: Adverse events/effects
Primary endpoint: (Serious) Adverse Event(s) occurrences of controlled P. vivax sporozoite human challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karnofsky Performance Status (KPS) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of complicated appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Motor vehicle accidents as a function of miles traveled
Endpoint domain: Mortality/survival
Primary endpoint: Number of on-the-job injuries
Endpoint domain: Adverse events/effects
Primary endpoint: QT interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fugl-Meyer Upper Motor Score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empathy levels in medical students
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of Light-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate reactions after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Status of coronary obturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Subjects Completing Regimen
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Secondary dislocation of fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Alteration of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of appearance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Radiation-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Local control evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure Related Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Alopecia grade after 3 cycles of eribulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in high-sensitivity C-reactive Protein value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: UDI-6 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prognostic markers of head and neck cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change in Montreal Cognitive Assessment (MoCA) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in Forward and Backward Digit and Corsi Span scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in Short Story test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in Copy and Recall of Rey-Osterrieth Complex Figure scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in Semantic and Phonological Verbal Fluency scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in Stroop color and word test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relief of signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Next-line Systemic Treatment - free survival
Endpoint domain: Mortality/survival
Primary endpoint: PSMA PET-CT accuracy and predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major molecular response (MMR) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of weight lost or gained from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Drug related adverse events meeting dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of death and major cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Endothelial Function measured as reactive hyperaemia index (RHI-EndoPAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid Femoral Pulse Wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BMI Z-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean urine osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Local Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in influenza RNA load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent of Patients With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for Serum Deferiprone and Deferiprone 3-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ for Serum Deferiprone and Deferiprone 3-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety (intensity and incidence of adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate according to RECIST v1.1 after 3 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Plasma Level (Cmax) of Metformin Hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histological prostate cancer aggressiveness (Gleason grade)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: level of oxycodone in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Risankizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Cmax) of Risankizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Alanine Aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change From Baseline in Aspartate Aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change From Baseline in Gamma-glutamyl Transferase (Gamma-GT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change From Baseline in Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in couple HIV testing uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intensity of humoral and cellular immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent agreement in diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmaxss of Metformin and Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Metformin and Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Blood Count-diff
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum HDL concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum LDL concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sallis Self Efficacy for Healthy Eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sallis Self Efficacy for Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with inappropriate antibiotic prescription for AECOPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Medication knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute Change From Cycle Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Women's satisfaction with midwifery based antenatal care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With Anti-V1V2 Total IgG Binding Antibody Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-V1V2 Total IgG Antibody Response Magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-V1V2 Subtypes Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-V1V2 IgG1, IgG2, IgG3 and IgG4 Antibody Response Magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Standard Deviation Lateral Position (SDLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of confirmed acute hepatitis A cases
Endpoint domain: Adverse events/effects
Primary endpoint: Negative predictive value of FFR-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of FFR-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of FFR-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-tumoral activity (objective response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of upper canine retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Warfarin related complications
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year heart failure (HF) rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Number of Adverse events per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response (Complete Remission [CR] and CR With Partial Recovery [CRp])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intramyocardial haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of DBS-nbM
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge, Attitudes, and Intended Behavior regarding hearing health care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Platelet Aggregation (MPA) to 20 μM ADP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC0-168
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of excess weight loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Yale Food Addiction Scale score at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle tightness level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue levels change
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reductions in caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stable blood glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Short chain fatty acid fermentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of depressive and anxiety disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: infection recurrence
Endpoint domain: Adverse events/effects